Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that 74 percent of surveyed U.S. neurologists indicate that they will prescribe Biogen Idec’s oral immunomodulator BG-12 for the treatment of relapsing-remitting multiple sclerosis (MS), and 32 percent expect to prescribe the drug to patients with clinically isolated syndrome—the highest levels of support expressed by surveyed neurologists who evaluated four late-stage emerging therapies profiled in the report. These findings likely reflect neurologists’ positive perception of BG-12’s clinical profile, which combines strong efficacy, good tolerability, convenient formulation, unique mechanism of action and a favorable safety profile to date.
READ MORE
READ MORE
===========================================================
– Click to: REGISTER – For our MS weekly e-Newsletter
“Providing You with ‘MS Views and News’, IS What We Do”
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
On the Fourth Wednesday of Each Month
Visit: StuMSradio – To Listen With Deanna and Stu
CALL-IN To listen, speak with us or speak with a guest
* Call (347) 215-9265 *
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Help us to educate $ DONATE NOW PLEASE $
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews